ED Coding & Reimbursement Alert - 2005 Issue 44
PHARMACEUTICALS: PAPs Should Not Assist Too Much
Subscribe or sign in to view the full article.
Article Overview
This piece explains a compliance-focused HHS Office of Inspector General bulletin about pharmaceutical patient assistance programs, especially for organizations that support Medicare Part D beneficiaries. It is relevant to manufacturers, compliance teams, and healthcare administrators who need a high-level understanding of permissible assistance models, charity-based alternatives, and the broader fraud-and-abuse context.
Why This Topic Matters
Organizations that help patients obtain outpatient prescription drugs need to understand the compliance boundaries described by HHS OIG, particularly when assistance involves Medicare Part D beneficiaries. The article highlights why program structure and charitable independence matter for risk management and beneficiary support.
What You Will Learn
- The compliance issues surrounding pharmaceutical patient assistance programs for Medicare Part D beneficiaries
- How HHS OIG frames lawful and potentially problematic assistance models
- The role of independent charity-based assistance programs in this context
- General considerations for manufacturers supporting patients who may enroll in Part D
Who Should Read This
- Pharmaceutical manufacturers
- Compliance officers
- Healthcare attorneys
- Patient assistance program administrators
- Revenue cycle and reimbursement professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com